Dallas, Texas 08/25/2014 (FINANCIALSTRENDS) – Ariad Pharmaceuticals, Inc.(NASDAQ:ARIA) the makers of one of the better known drugs for treating respiratory diseases, by the method of inhalation over traditional delivery system of drugs.
In recent quarters the rise and growth of ARIA remains wedded to the market performance of this favourite drug called Iclusig, (Ponatinib).
In the most recent quarter, which was the second quarter, the company reported financial results which distinctly marked the progress of the inhalation drug sales.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) Chairman and chief executive officer Harvey J. Berger noted that the sales of this drug was notable in both US as well as Europe.
The chief also noted that there were new trails which are planned for this drug in the coming months as well as a dose-ranging testing. The testing or the trial was to be conducted on the benefit as well as risk profiling of the approved drug.
However, the pioneering work done by Ariad Pharmaceuticals, Inc.(NASDAQ:ARIA) with respect to development of inhalation – based drug has meant that it needs to always remain ahead on the research and development curve, each consecutive quarter. And to prove the point the executive head in the conference call on earnings’ reported that fortunately, for this quarter the trial costs were minimally bringing down the expenses in this section. The company in totality spent lesser on this factor this quarter at 48.9 million which was lesser than previous quarter of 2013 by over 22%. Additionally, a trimming of the workforce in this segment also helped in lowering the overall costs of this business segment for Ariad Pharmaceuticals, Inc.(NASDAQ:ARIA).
As chief Berger noted, the current trend in Iclusig allows ARIA the comfort of offering a cash-positive guidance for 2014, remaining in-line with previous guidance issued.